Harmony Biosciences Holdings, Inc. 8K

Harmony Biosciences preannounced record preliminary Q2 2026 WAKIX revenue and reaffirmed 2026 guidance while announcing the resignation of its CFO and the appointment of an interim principal financial officer.

On July 16, 2026, Harmony Biosciences Holdings, Inc. preannounced preliminary, unaudited second quarter 2026 net product revenue for WAKIX of approximately $261 million, a record quarter reflecting 30% year-over-year and 21% sequential growth, and reaffirmed its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion, while also disclosing that Chief Financial Officer Glenn Reicin resigned effective July 16, 2026 to pursue other opportunities and that Senior Vice President and Controller Stephen Mollichella has been appointed Interim Principal Financial Officer as the company commences a search for a permanent CFO, with full Q2 2026 results to be released on August 4, 2026.

Filing Facts

CIK

1802665

Ticker

HRMY

Form

8K

Source Type

fda

Accession

0001104659-26-084095

Alert Tier

8